▲ Peaking
Business
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Oral Gilead IBD pill wipes out ulcerative colitis symptoms in mid‑stage trial, moving swiftly toward Phase III
Ibd
4 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Ibd
This hub groups 4 separate news trends connected to Ibd, spanning September 3, 2026 through October 20, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 37 article observations and 25 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
HPE, IBD Stock Of The Day, Breaks Out On Hiked Guidance, AI Momentum
HPE shares closed at a record high following a raised networking outlook and a $1.2 billion AI hardware order from cloud firm Vultr.
◼ Archived
Business
🔮 fades ✓
Micron, IBD Stock Of The Day, Surges Past Early Buy Point With Earnings Ahead
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
Antifungal therapy improves microbiome dynamics in inflammatory bowel disease
Antifungal treatment emerges as a potential new lever to reshape gut microbes for IBD patients battling Candida.